GLP-1 maintenance phase: what one month of data actually tells us

What did @britt2pretty4u actually say?

She tried a one-month "maintenance" break from weekly GLP-1 injections and found it genuinely hard. Her words: "I ain't ready and I'm ready to go back to once a week." She reported regaining about 7 pounds, going from 135 to 142, which she framed as intentional since her doctor flagged she was approaching underweight. She also noticed intense sweet cravings specifically in the off-injection week, something she said doesn't happen while actively dosing weekly.

The video is a personal experience update, not medical advice, and she's upfront about that. She's describing a real phenomenon that a lot of GLP-1 users encounter but rarely talk about openly: what happens when the drug's appetite-suppressing effects wear off between doses or during a full pause.

Does the science back this up?

Mostly, yes. The cravings-return-when-you-stop pattern is well-documented and tied directly to how GLP-1 receptor agonists work. This isn't willpower. It's pharmacology.

GLP-1 receptor agonists suppress appetite partly by acting on reward and satiety centers in the brain, including areas that regulate hedonic eating, which is eating for pleasure rather than hunger. Blundell et al. (2017, Diabetes, Obesity and Metabolism) showed that GLP-1 agonists reduce both hunger and food reward responses. When the drug clears your system, those pathways reactivate. The "I want everything sweet" experience she describes in her off week is consistent with that rebound in hedonic appetite.

On weight regain after stopping: the STEP 4 trial (Rubino et al., 2021, JAMA) showed that participants who stopped semaglutide after a weight-loss phase regained about two-thirds of their lost weight within a year. A one-week or one-month pause won't reproduce that scale of regain, but the directional signal is the same.

What did they get wrong (or right)?

She got more right than wrong here. The framing that GLP-1 maintenance requires psychological effort, "it's all up here," is accurate in the sense that the drug's behavioral scaffolding is partially removed when you reduce frequency or pause entirely. That said, calling it purely a mental game undersells the biological reality.

Where she's imprecise: framing the weight gain as entirely planned and controlled. Going from 135 to 142 in a month is a 7-pound gain. Some of that may have been intentional, but the timing with her off-week cravings suggests appetite rebound played a real role. It's worth being honest that those two things, wanting to gain a little weight and losing suppression-driven appetite control, can look identical on the scale but have different drivers.

Her doctor flagging that she was approaching underweight is worth taking seriously. BMI thresholds aside, being underweight carries its own health risks, including bone density loss and immune function impacts (Feuerstein and Cheifetz, 2010, Gastroenterology and Hepatology). That clinical check-in sounds appropriate.

What should you actually know?

GLP-1 medications are not a permanent cure for appetite dysregulation. The weight regain data after stopping is consistent and not subtle. The STEP 1 trial extension (Wilding et al., 2022, Nature Medicine) confirmed that most weight lost on semaglutide returned within a year of stopping the drug. This isn't a personal failure. It reflects the underlying biology of obesity as a chronic condition.

If you're considering a maintenance protocol, defined as reducing injection frequency rather than stopping entirely, the evidence base for what that looks like is thin. There is no widely studied protocol for "every other week" maintenance dosing. Some clinicians try it, but it's largely off-label experimentation. The cravings and regain she experienced are a predictable consequence of lower circulating drug levels, not a sign she did something wrong.

• Sweet cravings returning off-drug is a real biological rebound, not just weak willpower.
• Weight regain when stopping GLP-1s is expected and well-documented in clinical trials.
• Her doctor's concern about being underweight is a legitimate clinical signal worth heeding.
• "Maintenance mode" at reduced frequency isn't a formalized protocol, it's an experiment.

Bottom line

This video is a rare honest account of what GLP-1 dose reduction actually feels like, not a sales pitch, not a transformation post. She's describing real pharmacological withdrawal effects in plain language. The science broadly supports her experience. The gap is in framing the weight regain as fully intentional when appetite rebound almost certainly played a role. Credit where it's due: she went back to her doctor, took the underweight concern seriously, and is being transparent about the difficulty. That's more than most GLP-1 content creators offer.